European Network of Gynecological Oncological Trial Groups (ENGOT)

What European Network of Gynecological Oncological Trial Groups (ENGOT) does

ENGOT (European Network of Gynecological Oncological Trial Groups) is a non-profit research network founded in 2007 under the European Society of Gynaecological Oncology (ESGO), headquartered administratively in Brussels, Belgium. It coordinates cooperative clinical trials in gynecological oncology across 22 national and regional trial groups spanning 34 European countries, enabling multinational studies and harmonizing operational standards that individual national groups could not achieve independently. The network serves three primary stakeholder groups: gynecological cancer patients who gain access to cutting-edge clinical trials across Europe, pharmaceutical companies seeking efficient multi-country trial execution, and academic investigators who collaborate through the network on translational and clinical research.

ENGOT's core operational products include clinical trial coordination spanning ovarian, endometrial, cervical, vulvar, and basket cancer categories; a Translational Research Group building a standardized pan-European biobank with unified SOPs and clinical datasets; an Early Drug Development Group accelerating first-in-human through registration trials; and a Rare Tumour Group focused on novel trial designs for rare gynecological malignancies. The network also delivers educational services through the Gynaecological Cancer Academy (GCA) workshops, which train approximately 42 senior investigators per session, and the ENGOT Masterclass for Operationals covering clinical trial methodology and GCP training.

The business model operates on a non-profit basis, funded through grant funding and pharmaceutical industry sponsorship of clinical trials and educational programs. ENGOT offers pharmaceutical partners a ready-to-go efficient structure for multi-national European trials, with academic expertise and standardized trial coordination infrastructure. Major industry partners include AstraZeneca, Merck/MSD, GSK, Pfizer, Gilead Sciences, Daiichi Sankyo, Eli Lilly, BioNTech, and Corcept Therapeutics, among others. The network is led by Clinical Chair Isabelle Ray-Coquard and Operational Chair Elena Biagioli, with an ENGOT Manager (Zuzana Seps) handling partner collaborations. Revenue figures are not disclosed, and the network has no independent ownership structure, operating entirely under ESGO.

Name

European Network of Gynecological Oncological Trial Groups (ENGOT)

Legal name

European Society of Gynaecological Oncology (ESGO)

Website

https://engot.esgo.org

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

ENGOT is a non-profit research network under ESGO that coordinates cooperative clinical trials in gynecological oncology across 22 trial groups in 34 European countries, serving cancer patients, pharmaceutical sponsors, and academic investigators through trial coordination, translational research, and educational programs.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)

akta.pro secondary industries

Investigator & Site Training / GCP Support (HLAGACAF), Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK)

Keywords

• Gynecological oncology research
• Clinical trial coordination
• Academic clinical trials
• Translational research
• European research network

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Grant Funding: ENGOT receives grant funding to support its mission of coordinating clinical trials and training the next generation of professionals in gynecological oncology research.
2. Pharmaceutical Industry Sponsorship: ENGOT coordinates industry-sponsored clinical trials for pharmaceutical companies seeking to perform multinational studies in Europe, offering ready-to-go efficient structure and academic expertise.

Distribution channels2 records

Marketing channels6 records

Core offering

ENGOT coordinates and promotes cooperative clinical trials in gynecological oncology across Europe through a network of 22 trial groups from 34 countries. It harmonizes operational standards, supports translational research and biobanking, runs early drug development and rare tumor programs, and provides educational programs (Gynaecological Cancer Academy workshops and Masterclass for Operationals) to develop the next generation of trial leaders.

Product overview

ENGOT is a research network of the European Society of Gynaecological Oncology (ESGO) that coordinates clinical trials across 22 trial groups from 34 European countries. The organization operates through several core functions: clinical trials coordination, translational research (including biobanking), rare tumor research, and early drug development. Additionally, ENGOT provides educational programs including the Gynaecological Cancer Academy (GCA) workshops for developing future oncology leaders and Masterclass training for clinical trial operational staff. The network enables European patients to access clinical trials and facilitates multinational academic and industry-sponsored clinical studies in gynecological oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• ENGOT Clinical Trials Coordination Coordination and promotion of cooperative clinical trials on gynecological cancer patients across Europe through a network of 22 trial groups in 34 European countries, enabling multinational studies and harmonizing operational aspects.
• Translational Research Program Program to establish European biobanks for gynecological malignancies and discover new targets and biomarkers to predict response to classical and targeted therapies, using standardized SOPs and clinical data sets across the network.
• Rare Tumour Group Network that accelerates development of new therapies for rare gynecological cancers through European collaboration, novel trial designs, and strong scientific rationale.
• Early Drug Development Group Develops a network of early phase trial centers and investigators to deliver early phase clinical trials with strong scientific rationale, accelerating compound development from first-in-human through randomized registration trials.
• Gynaecological Cancer Academy (GCA) Educational program of workshops, training modules, and mentorship designed to develop the next generation of leaders in gynecological oncology, including clinical trial design and conduct.
• ENGOT Masterclass for Operationals Webinar-based educational series covering gynecological oncology topics, clinical trial basics, study setup, and GCP training for operationals and project managers of clinical trials within ENGOT groups.

Quantifiable outcome

• All prespecified subgroups experienced meaningful survival benefits in ROSELLA trial across participating ENGOT sites
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

16 partnerships are on record, tiered minor and core.

• AstraZenecaminorOthers · 13 November 2024AstraZeneca sponsored the 2024 ENGOT GCA Workshop held November 13-15, 2024 in Stresa, Italy.
• BioNTechminorOthers · 13 November 2024BioNTech sponsored the 2024 ENGOT GCA Workshop held November 13-15, 2024 in Stresa, Italy.
• Gilead SciencesminorOthers · 13 November 2024Gilead Sciences sponsored the 2024 ENGOT GCA Workshop held November 13-15, 2024 in Stresa, Italy.
• GSKminorOthers · 13 November 2024GSK sponsored the 2024 ENGOT GCA Workshop held November 13-15, 2024 in Stresa, Italy.
• ImmunogenminorOthers · 13 November 2024Immunogen sponsored the 2024 ENGOT GCA Workshop held November 13-15, 2024 in Stresa, Italy.
• PfizerminorOthers · 13 November 2024Pfizer supported the 2024 ENGOT GCA Workshop with a grant, held November 13-15, 2024 in Stresa, Italy.
• TORL BiominorOthers · 13 November 2024TORL Bio sponsored the 2024 ENGOT GCA Workshop held November 13-15, 2024 in Stresa, Italy.
• ZentalisminorOthers · 13 November 2024Zentalis sponsored the 2024 ENGOT GCA Workshop held November 13-15, 2024 in Stresa, Italy.
• MenStemminorOthers · 13 November 2024MenStem sponsored the 2024 ENGOT GCA Workshop held November 13-15, 2024 in Stresa, Italy.
• PharmaandminorOthers · 13 November 2024Pharmaand sponsored the 2024 ENGOT GCA Workshop held November 13-15, 2024 in Stresa, Italy.
• European Society of Gynaecological Oncology (ESGO)coreStrategic or Co-development PartnerENGOT is a research network of ESGO. ESGO is the parent organization that founded ENGOT in 2007. The ESGO registered office at Avenue Emmanuel Mounier 83/11, Brussels serves as ENGOT's administrative base. ESGO organizes the annual European Gynaecological Oncology Congress where ENGOT presents trial results.
• Corcept TherapeuticscoreStrategic or Co-development PartnerCorcept conducted the pivotal Phase 3 ROSELLA trial through ENGOT, with 381 patients enrolled across five international gynecologic oncology trial groups spanning multiple continents. ENGOT sites contributed to the trial that supported FDA approval of Lifyorli in March 2026.
• Merck (MSD)coreStrategic or Co-development PartnerMerck conducted the Phase 3 KEYNOTE-B96 trial through ENGOT's MaNGO group, showing KEYTRUDA plus chemotherapy improved overall survival in platinum-resistant recurrent ovarian cancer. CHMP adopted positive opinion for this indication.
• Daiichi Sankyo and AstraZenecacoreStrategic or Co-development PartnerDaiichi Sankyo and AstraZeneca are conducting the DESTINY-Endometrial02 Phase 3 trial evaluating ENHERTU in endometrial cancer through ENGOT sites, with first patient dosed in December 2025.
• Eli LillycoreStrategic or Co-development PartnerEli Lilly's sofetabart mipitecan received FDA Breakthrough Therapy designation based on Phase 1a/b results. Lilly initiated Phase 3 FRAmework-01 trial investigating the ADC through ENGOT network.
• ENGAGe (European Network of Gynaecological Cancer Advocacy Groups)coreStrategic or Co-development PartnerENGAGe is the patient advocacy counterpart to ENGOT. Together they created a clinical trials brochure tailored to patient needs. The 2026 GCA Workshop introduces collaboration with patient advocacy groups, with each team including an ENGAGe representative.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• MaNGO (Mario Negri Gynecologic Oncology): The Italian cooperative group at Istituto Mario Negri whose Translational Research head, Elena Biagioli, currently serves as ENGOT's Operational Chair. MaNGO conducts ENGOT-affiliated trials (including the KEYNOTE-B96 program with Merck) and is a comparable national gyn-onc research group.
• GCGI / Nordic Society of Gynaecological Oncology (NSGO): Nordic cooperative group conducting gynecologic oncology clinical trials across Denmark, Sweden, Norway, Finland, and Iceland. NSGO is a regional ENGOT member and direct peer in multinational Nordic gyn-onc trial execution.
• Gynecologic Cancer InterGroup (GCIG): An international umbrella organization of cooperative groups conducting gynecologic cancer clinical trials, of which ENGOT is a member. GCIG and ENGOT overlap substantially in mission and members, with GCIG functioning as a meta-network of which ENGOT is the European arm.
• AGO (Arbeitsgemeinschaft Gynäkologische Onkologie): The German Gynecological Oncology Working Group, one of ENGOT's 22 member national trial groups and a major contributor of patients to ENGOT-coordinated trials. AGO is a national-level peer within the ENGOT umbrella that also runs its own portfolio of gyn-onc trials.
• NRG Oncology: The US National Cancer Institute-sponsored cooperative group that resulted from the merger of the Gynecologic Oncology Group (GOG) with other oncology research bases. NRG is the principal North American counterpart to ENGOT for gynecologic oncology clinical trials, sharing the cooperative-group trial coordination model and frequently collaborating on transatlantic Phase 3 studies.
• GINECO (Groupe d'Investigateurs Nationaux pour l'Étude des Cancers de l'Ovaire): France's national cooperative group for gynecologic oncology, led by ENGOT's current Clinical Chair Isabelle Ray-Coquard. GINECO is both an ENGOT member group and a key European peer running parallel national trial programs in ovarian and other gynecologic cancers.

Broad incumbents

• BIG (Breast International Group): An international not-for-profit organization coordinating large-scale breast cancer clinical trials across dozens of national cooperative groups. BIG shares ENGOT's cooperative-group coordination model and serves as a structural analog for how pan-disease trial networks operate in oncology.
• European Society for Medical Oncology (ESMO): The leading European professional society for medical oncology that sets guidelines, hosts the annual ESMO Congress, and shapes clinical trial standards. ESMO is a broader ecosystem player that overlaps with ENGOT in gynecologic cancer trial promotion and congress-based dissemination.
• European Organisation for Research and Treatment of Cancer (EORTC): The pan-European cooperative group covering all major cancer types including gynecological cancers. EORTC overlaps with ENGOT in coordinating multinational European oncology trials but operates across the full oncology spectrum rather than specializing in gynecologic oncology.

Regional players

• NCRI (National Cancer Research Institute): The UK umbrella partnership of cancer research funders and groups that coordinates UK clinical trial activity including in gynecological cancers. NCRI serves as the principal UK counterpart within the ENGOT ecosystem and a regional peer in trial coordination and prioritization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/european-society-of-gynaecological-oncology

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about European Network of Gynecological Oncological Trial Groups (ENGOT)